AiCella deploys AI to create innovative tools that streamline the therapeutic manufacturing processes in cell and gene therapy, thereby reducing bottlenecks, lowering costs, with the goal of enhancing patient outcomes.

Visit Website

Branca Bunús Ltd is an innovative Irish biotechnology company pioneering next-generation polymer-based gene delivery technologies for cell and gene therapy (CGT). A spin-out from University College Dublin, Branca Bunús translates world-leading polymer chemistry into high-performance transfection solutions that enable efficient, scalable, and cost-effective gene delivery from research through to GMP manufacturing. The company’s flagship platform, BrPERFect®, is built on proprietary Hyperbranched Poly(Amine-Ester) (HPAE) polymer technology and has demonstrated outstanding performance in lentiviral vector (LVV) production. BrPERFect® enables high-titer, reproducible LVV manufacturing with simplified workflows and reduced reagent usage, delivering significant advantages over conventional PEI and lipid-based reagents. Its robustness and scalability make it particularly well suited for industrial-scale viral vector production. These capabilities directly support the advancement of next-generation CAR-T therapies, including emerging in vivo CAR-T approaches, where reliable, efficient, and scalable vector manufacturing is critical. In addition to LVV production, BrPERFect® supports AAV manufacturing and recombinant protein expression, providing a versatile platform across multiple bioproduction applications. Branca Bunús partners with biotech companies, CDMOs, and academic institutes worldwide to accelerate the translation of advanced therapies from discovery to clinical and commercial stages. The company’s polymer delivery technologies address the CGT sector’s growing demand for safer, more sustainable, and high-yield biomanufacturing solutions. Supported by Enterprise Ireland, Branca Bunús combines scientific excellence with a clear commercial vision: to empower the global CGT community with high-performance polymer gene delivery tools that enable scalable viral vector production and accelerate the development of in-vivo transformative therapies. Learn more at www.brancabunus.com.

Visit Website

The TROVO system from Enrich Biosystems is an advanced benchtop cell discovery platform that enables researchers to functionally profile, monitor, and retrieve live cells based on behavior — not just surface markers or static measurements. The TROVO system uses a microwell-based, microfluidics-free technology to image, analyze and gently retrieve live cells to accelerate discovery in immuno-oncology and cell therapy development.

Visit Website

IamFluidics is a microfluidics technology company pioneering in-air microfluidics to enable scalable, reproducible 2D and 3D cell culture for advanced cell therapy manufacturing. Its proprietary platform generates uniform droplets at industrial throughput, allowing precise control over cell microenvironments without the constraints of traditional chip-based systems. The company provides R&D and industrial-scale equipment supporting translation from process development to manufacturing. IamFluidics also develops dissolvable microcarrier products, including solutions co-developed with Rousselot, enabling high-yield expansion and efficient harvesting of adherent cells for cell therapies. In addition, the company offers high-throughput cell encapsulation services for 3D spheroid and organoid production, generating thousands of uniform microtissues per second with tight control over size, composition, and reproducibility. By bridging laboratory precision with manufacturing-scale performance, IamFluidics enables the scalable production of next-generation cell and gene therapies.

Visit Website

ReelReactor™ is a cutting-edge continuous micro-batch reactor designed to revolutionize biologics manufacturing. Unlike traditional batch systems, which suffer from poor scalability, inconsistent quality, and high costs due to time-dependent reactions, ReelReactor enables precise, scalable, and cost-effective continuous production. Engineered for cell and gene therapy and other biologics, ReelReactor features functionally closed, sterile single-use consumables and biologically inert wetted materials. Its unique design ensures constant, gentle mixing, preserving product integrity, and it seamlessly integrates into larger workflows, eliminating bottlenecks. By bridging the gap between batch and continuous manufacturing, ReelReactor empowers biopharma companies to accelerate development, reduce manufacturing costs, and improve product consistency. Whether for feasibility studies, small-scale manufacturing, or full-scale production, ReelReactor provides an innovative, flexible platform to meet the evolving needs of modern bioprocessing.

Telos Biotechnology is revolutionizing cell therapy manufacturing with TELOVANCE™, a proprietary telomere-lengthening platform designed to enhance the expansion and efficacy of engineered cell therapies. Telos’ breakthrough technology addresses a critical limitation in CAR T-cell therapy—T-cell senescence and exhaustion, which contribute to poor long-term remission rates. The Challenge: CAR T-cell therapy has transformed cancer treatment, but nearly 50% of adult patients fail to achieve durable responses. One major contributor is immunosenescence, where T-cells progressively lose function due to telomere shortening, limiting their expansion potential and persistence. The Solution: TELOVANCE™ is a recombinant human telomerase holoenzyme that transiently extends telomeres during ex-vivo CAR T-cell manufacturing, increasing replicative lifespan and cytotoxicity without genetic modification. Our in-vitro and in-vivo data demonstrate that TELOVANCE-treated CAR T-cells outperform untreated counterparts in durability and anti-tumor activity. The telomerase enzyme is naturally degraded within 48 hours, ensuring safe and transient telomere elongation. Telos is actively collaborating with leading biotech, pharma and CDMO companies to integrate TELOVANCE™ into next-generation cell therapies. For partnership inquiries, visit TelosBio.com or email info@telosbio.com .